The effect of erythromycin on the pharmacokinetics of rosuvastatin

European Journal of Clinical Pharmacology

Volumn 59, Issue 1, 2003, Pages 51-56

  Cooper, K J ^a   Martin, P D ^a   Dane, A L ^a   Warwick, M J ^a   Raza, A ^a   Schneck, D W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CYP3A4 Pharmacokinetics; Erythromycin; Rosuvastatin

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0038130937     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0573-7     Document Type: Article

References (24)

1. Olsson AG, Pears J, McKellar J, Mizan J, Raza A (2001) Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88:504-508
2. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H (2002) Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 89:268-275
3. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258
4. von Rosensteil NA, Adam M (1995) Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 13:105-122
5. Siedlik PH, Olson SC, Yang B-B, Stern RH (1999) Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 39:501-504
6. Kantola T, Kivistö KT, Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64:177-182
7. Kantola T, Kivistö KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65
8. Martin PD, Dane AL, Schneck DW, Warwick MJ (2000) Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects (abstract 48). J Clin Pharmacol 40:1056
9. McCormick AD, McKillop D, Butters CJ, Miles GS, Baba T, Touchi A, Yamaguchi Y (2000) ZD4522 an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems (abstract 46). J Clin Pharmacol 40:1055
10. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ (2002) No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 42:1116-1121
11. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW (2003) Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin. Br J Clin Pharmacol 53:94-99
12. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV (2002) Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther (in press)
13. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV (2002) The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58:527-531
14. Hofsli E, Nissen-Meyer J (1989) Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer 44:149-154
15. Nezasa K, Higaki K, Hasegawa H, Inazawa K, Takeuchi M, Yukawa T, McTaggart F, Nakano M (2000) Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat (abstract MOP21: W6). Atherosclerosis 151:39
16. Nezasa K, Higaki K, Yukawa T, Inazawa K, Hasegawa H, Nakano M (2002) Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 30:1158-1163
17. Brown CDA, Windass A, Bleasby K, Lauffart B (2001) Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C (abstract). Atheroscler [Suppl 2]:90
18. Hull CK, Penman AD, Smith CK, Martin PD (2002) Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. J Chromatogr B Anal Technol Biomed Life Sci 772:219-228
19. Tucker GT, Houston JB, Huang S-M (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential toward a consensus. Clin Pharmacol Ther 70:103-114
20. Parfitt K (1999) Martindale: the extra pharmacopoeia, 32nd edin. Pharmaceutical, UK
21. Catnech SM, Fairclough PD (1992) Erythromycin and the gut. Gut 33:397-401
22. Michniewicz BM, Black AE, Sinz MW, Woolf TF (1994) In vitro and in vivo metabolism of atorvastatin (CI-981) (abstract). ISSX Proc 6:93
23. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP (1997) In vitro metabolism of simvastatin in humans (SBT) identification of metabolizing enzymes and effect of the drug on hepatic P450 s. Drug Metab Dispos 25:1191-1199
24. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing K-F, Christians U (1999) Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173-179